APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Selected research

Market Structure

Global Duchenne Muscular Dystrophy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025184 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

Read the full market overview

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

This report provides an overview of the global Duchenne Muscular Dystrophy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Duchenne Muscular Dystrophy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Duchenne Muscular Dystrophy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Duchenne Muscular Dystrophy market size, projected growth trends, production technologies, key applications, and end-use industries.

Duchenne Muscular Dystrophy Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Segment by Type

Exondys 51

Emflaza

Translarna

Duchenne Muscular Dystrophy Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Duchenne Muscular Dystrophy market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Duchenne Muscular Dystrophy Industry Trends Table 2. Duchenne Muscular Dystrophy Industry Drivers Table 3. Duchenne Muscular Dystrophy Industry Opportunities and Challenges Table 4. Duchenne Muscular Dystrophy Industry Restraints Table 5. Global Duchenne Muscular Dystrophy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Duchenne Muscular Dystrophy Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Duchenne Muscular Dystrophy Sales by Manufacturers (K Doses) & (2021-2026) Table 8. Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers Table 9. Global Duchenne Muscular Dystrophy Average Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 10. Global Duchenne Muscular Dystrophy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Duchenne Muscular Dystrophy Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Duchenne Muscular Dystrophy Manufacturers, Product Type & Application Table 13. Global Duchenne Muscular Dystrophy Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Duchenne Muscular Dystrophy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Exondys 51 Table 17. Major Manufacturers of Emflaza Table 18. Major Manufacturers of Translarna Table 19. Global Duchenne Muscular Dystrophy Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 20. Global Duchenne Muscular Dystrophy Sales by Type (2021-2026) & (K Doses) Table 21. Global Duchenne Muscular Dystrophy Sales by Type (2027-2032) & (K Doses) Table 22. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2026) Table 23. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2027-2032) Table 24. Global Duchenne Muscular Dystrophy Revenue by Type 2021 VS 2025 VS 2032 (K Doses) Table 25. Global Duchenne Muscular Dystrophy Revenue by Type (2021-2026) & (K Doses) Table 26. Global Duchenne Muscular Dystrophy Revenue by Type (2027-2032) & (K Doses) Table 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2026) Table 28. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Home Care Table 32. Global Duchenne Muscular Dystrophy Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 33. Global Duchenne Muscular Dystrophy Sales by Application (2021-2026) & (K Doses) Table 34. Global Duchenne Muscular Dystrophy Sales by Application (2027-2032) & (K Doses) Table 35. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2026) Table 36. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2027-2032) Table 37. Global Duchenne Muscular Dystrophy Revenue by Application 2021 VS 2025 VS 2032 (K Doses) Table 38. Global Duchenne Muscular Dystrophy Revenue by Application (2021-2026) & (K Doses) Table 39. Global Duchenne Muscular Dystrophy Revenue by Application (2027-2032) & (K Doses) Table 40. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2026) Table 41. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2027-2032) Table 42. Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Duchenne Muscular Dystrophy Sales by Region (2021-2026) & (K Doses) Table 44. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2021-2026) Table 45. Global Duchenne Muscular Dystrophy Sales Forecasted by Region (2027-2032) & (K Doses) Table 46. Global Duchenne Muscular Dystrophy Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 48. North America Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 49. North America Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 50. Europe Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 51. Europe Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 52. Europe Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 53. Asia Pacific Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 54. Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 55. Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 56. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Doses) Table 57. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2021-2026) & (K Doses) Table 58. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2027-2032) & (K Doses) Table 59. Global Duchenne Muscular Dystrophy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Duchenne Muscular Dystrophy Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Duchenne Muscular Dystrophy Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2021-2026) Table 63. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2027-2032) Table 64. Sarepta Therapeutics Company Information Table 65. Sarepta Therapeutics Business Overview Table 66. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 68. Sarepta Therapeutics Recent Development Table 69. PTC Therapeutics Company Information Table 70. PTC Therapeutics Business Overview Table 71. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio Table 73. PTC Therapeutics Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Duchenne Muscular Dystrophy Product Portfolio Table 78. Pfizer Recent Development Table 79. Bristol-Myers Squibb Company Information Table 80. Bristol-Myers Squibb Business Overview Table 81. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio Table 83. Bristol-Myers Squibb Recent Development Table 84. Italfarmaco Company Information Table 85. Italfarmaco Business Overview Table 86. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Italfarmaco Duchenne Muscular Dystrophy Product Portfolio Table 88. Italfarmaco Recent Development Table 89. Santhera Pharmaceuticals Company Information Table 90. Santhera Pharmaceuticals Business Overview Table 91. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio Table 93. Santhera Pharmaceuticals Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Duchenne Muscular Dystrophy Distributors List Table 97. Duchenne Muscular Dystrophy Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy Product Image Figure 2. Global Duchenne Muscular Dystrophy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy Market Size (2021-2032) & (US$ Million) Figure 4. Global Duchenne Muscular Dystrophy Sales (2021-2032) & (K Doses) Figure 5. Global Duchenne Muscular Dystrophy Average Price (USD/Dose) & (2021-2032) Figure 6. Global Top 5 and 10 Duchenne Muscular Dystrophy Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Exondys 51 Image Figure 9. Emflaza Image Figure 10. Translarna Image Figure 11. Global Duchenne Muscular Dystrophy Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 12. Global Duchenne Muscular Dystrophy Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2032) Figure 14. Global Duchenne Muscular Dystrophy Revenue by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 15. Global Duchenne Muscular Dystrophy Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Home Care Image Figure 20. Global Duchenne Muscular Dystrophy Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 21. Global Duchenne Muscular Dystrophy Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2032) Figure 23. Global Duchenne Muscular Dystrophy Revenue by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 24. Global Duchenne Muscular Dystrophy Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2032) Figure 26. North America Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 27. North America Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2032) Figure 28. U.S. Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 29. Canada Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 30. Mexico Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 31. Europe Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 32. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2032) Figure 33. Germany Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 34. France Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 35. U.K. Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 36. Italy Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 37. Netherlands Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 38. Asia Pacific Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 39. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2032) Figure 40. China Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 41. Japan Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 42. South Korea Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 43. Southeast Asia Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 44. India Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 45. Australia Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 46. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 47. South America, Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2021-2032) Figure 48. Brazil Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 49. South Africa Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 50. Saudi Arabia Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 51. Turkey Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 52. Argentina Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 53. UAE Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 54. Egypt Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 55. Chile Duchenne Muscular Dystrophy Sales and Growth Rate (2021-2032) & (K Doses) Figure 56. Global Duchenne Muscular Dystrophy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Duchenne Muscular Dystrophy Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Figure 59. North America Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Figure 61. Europe Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Duchenne Muscular Dystrophy Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Duchenne Muscular Dystrophy Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Duchenne Muscular Dystrophy Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys 51
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Duchenne Muscular Dystrophy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Duchenne Muscular Dystrophy Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Duchenne Muscular Dystrophy Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Duchenne Muscular Dystrophy Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy Industry Restraints
3 Duchenne Muscular Dystrophy Market by Manufacturers
  1. 3.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Duchenne Muscular Dystrophy Sales by Manufacturers (2021-2026)
  3. 3.3 Global Duchenne Muscular Dystrophy Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Duchenne Muscular Dystrophy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Duchenne Muscular Dystrophy Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Duchenne Muscular Dystrophy Manufacturers, Product Type & Application
  7. 3.7 Global Duchenne Muscular Dystrophy Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Duchenne Muscular Dystrophy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Duchenne Muscular Dystrophy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Duchenne Muscular Dystrophy Tier 1, Tier 2, and Tier 3
4 Duchenne Muscular Dystrophy Market by Type
  1. 4.1 Duchenne Muscular Dystrophy Type Introduction
  2. 4.1.1 Exondys 51
  3. 4.1.2 Emflaza
  4. 4.1.3 Translarna
  5. 4.2 Global Duchenne Muscular Dystrophy Sales by Type
  6. 4.2.1 Global Duchenne Muscular Dystrophy Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Duchenne Muscular Dystrophy Sales by Type (2021-2032)
  8. 4.2.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2021-2032)
  9. 4.3 Global Duchenne Muscular Dystrophy Revenue by Type
  10. 4.3.1 Global Duchenne Muscular Dystrophy Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Duchenne Muscular Dystrophy Revenue by Type (2021-2032)
  12. 4.3.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021-2032)
5 Duchenne Muscular Dystrophy Market by Application
  1. 5.1 Duchenne Muscular Dystrophy Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Home Care
  5. 5.2 Global Duchenne Muscular Dystrophy Sales by Application
  6. 5.2.1 Global Duchenne Muscular Dystrophy Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Duchenne Muscular Dystrophy Sales by Application (2021-2032)
  8. 5.2.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2021-2032)
  9. 5.3 Global Duchenne Muscular Dystrophy Revenue by Application
  10. 5.3.1 Global Duchenne Muscular Dystrophy Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Duchenne Muscular Dystrophy Revenue by Application (2021-2032)
  12. 5.3.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021-2032)
6 Global Duchenne Muscular Dystrophy Sales by Region
  1. 6.1 Global Duchenne Muscular Dystrophy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Duchenne Muscular Dystrophy Sales by Region (2021-2032)
  3. 6.2.1 Global Duchenne Muscular Dystrophy Sales by Region (2021-2026)
  4. 6.2.2 Global Duchenne Muscular Dystrophy Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Duchenne Muscular Dystrophy Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Duchenne Muscular Dystrophy Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Duchenne Muscular Dystrophy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Duchenne Muscular Dystrophy Revenue by Region
  1. 7.1 Global Duchenne Muscular Dystrophy Revenue by Region
  2. 7.1.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Duchenne Muscular Dystrophy Revenue by Region (2021-2026)
  4. 7.1.3 Global Duchenne Muscular Dystrophy Revenue by Region (2027-2032)
  5. 7.1.4 Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Duchenne Muscular Dystrophy Revenue (2021-2032)
  8. 7.2.2 North America Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Duchenne Muscular Dystrophy Revenue (2021-2032)
  11. 7.3.2 Europe Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Duchenne Muscular Dystrophy Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Duchenne Muscular Dystrophy Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Duchenne Muscular Dystrophy Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sarepta Therapeutics
  2. 8.1.1 Sarepta Therapeutics Company Information
  3. 8.1.2 Sarepta Therapeutics Business Overview
  4. 8.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  6. 8.1.5 Sarepta Therapeutics Recent Developments
  7. 8.2 PTC Therapeutics
  8. 8.2.1 PTC Therapeutics Company Information
  9. 8.2.2 PTC Therapeutics Business Overview
  10. 8.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
  12. 8.2.5 PTC Therapeutics Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Italfarmaco
  26. 8.5.1 Italfarmaco Company Information
  27. 8.5.2 Italfarmaco Business Overview
  28. 8.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
  30. 8.5.5 Italfarmaco Recent Developments
  31. 8.6 Santhera Pharmaceuticals
  32. 8.6.1 Santhera Pharmaceuticals Company Information
  33. 8.6.2 Santhera Pharmaceuticals Business Overview
  34. 8.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
  36. 8.6.5 Santhera Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Duchenne Muscular Dystrophy Value Chain Analysis
  2. 9.1.1 Duchenne Muscular Dystrophy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Duchenne Muscular Dystrophy Production Mode & Process
  6. 9.2 Duchenne Muscular Dystrophy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Duchenne Muscular Dystrophy Distributors
  9. 9.2.3 Duchenne Muscular Dystrophy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst